pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

ADA reviews June conference disruptions, finds no censorship of editorial

Sep 1, 2026·read at STAT ↗Neutral

American Diabetes Association CEO Charles "Chuck" Henderson apologized after several attendees were removed from the June 5 Scientific Sessions in New Orleans for repeated disruptions. He said the apology was directed both to the individuals involved and to the broader diabetes community.

An independent review conducted by five volunteer investigators was completed to examine the incident. The review focused on two main allegations: that the ADA suppressed a viewpoint critical of federal research cuts and that attendees were removed for distributing that editorial.

The reviewers found no evidence of censorship. The editorial in question had been published in the ADA's own journal, Diabetes Care, and the removals were based on conduct that violated the conference code of conduct. Henderson urged that the findings be shared directly, without further narrative distortion.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: Diabetes association CEO: What an independent review says happened at the ADA’s controversial June conference”

read at STAT ↗
1,095 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Type 2 Diabetes20

related stories

  • May 11Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trialBioPharma Dive
  • May 8Trump reportedly plans to fire FDA Commissioner MakarySTAT
  • May 8Lilly to invest extra $4.5B across Indiana manufacturingBioPharma Dive
  • May 8Lilly, Gilead lead pharma’s M&A boomBioPharma Dive
  • May 7Official leading CDC’s cruise ship program retiresSTAT